Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

计划入组 4 人 · 首次发布于 2003 年 1 月 27 日

Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma

计划入组 81 人 · 首次发布于 2022 年 1 月 28 日

Ibrutinib for Relapsed or Refractory Mantle Cell Lymphoma

计划入组 88 人 · 首次发布于 2019 年 8 月 20 日

FOX01 inhibitor program (mantle cell lymphoma)

Ibrutinib(Imbruvica)

C₂₅H₂₄N₆O₂

Acalabrutinib(Calquence)

C₂₆H₂₃N₇O₂ · Rx

AUSTRALASIAN LEUKAEMIA & LYMPHOMA GROUP

Australia

Gamida Cell

Israel

GAMIDA CELL INC.

United States

Acalabrutinib Receives FDA Approval for Previously Untreated Mantle Cell Lymphoma

FDA Grants Priority Review to Calquence for Untreated Mantle Cell Lymphoma

Sonrotoclax Plus Zanubrutinib Shows Promise in Relapsed/Refractory Mantle Cell Lymphoma with 78% Response Rate